The anti-Xa low molecular weight heparin (LMWH) assay is intended to quantify the plasma levels of LMWH during the treatment of thromboembolic accidents. Monitoring Anti-Xa LMWH helps healthcare providers optimize the dose of LMWH and ensure effective anticoagulation therapy in patients with high-risk trauma and burns.

References:

• Gremillet M, Talon L, Lebreton A, Sinegre T. Monitoring heparin therapy: stability of two different anti-Xa assays using blood samples collected in citrate-containing and CTAD tubes. Thrombosis Journal. 2023 Feb 20;21(1):21.  Accessed on 19 January 2024.
• Xu L, Sun Y, Wang S, Li C, Mao Y. Anti-Xa level monitoring of low-molecular-weight heparin during intermittent venovenous hemofiltration. Ann Hematol. 2023 Aug;102(8):2251-2256. doi: 10.1007/s00277-023-05290-7. Accessed on 19 January 2024.
• Wei MY, Ward SM. The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis. Hematol Rep. 2015 Nov 23;7(4):5844. doi: 10.4081/hr.2015.5844. Accessed on 19 January 2024.
• Data on File: PureLab DOS V5, November 10th, 2023.